Centre for Health Solutions-Kenya (CHS), Nairobi, Kenya.
Division of Global HIV and TB, Centers for Disease Control and Prevention, Nairobi, Kenya.
AIDS Res Hum Retroviruses. 2022 Jun;38(6):480-490. doi: 10.1089/AID.2021.0112. Epub 2022 Mar 30.
Expanded access to HIV treatment services has improved outcomes for children and adolescents living with HIV in Kenya. Minimal data are available on these outcomes. We describe temporal trends in outcomes for children and adolescents initiating antiretroviral therapy (ART) from 2004 to 2014 at sites supported by Centre for Health Solutions-Kenya, in central Kenya. We retrospectively analyzed data from children 0-9 years of age ( = 3,519) and adolescents 10-19 years of age ( = 1,663) living with HIV, who newly initiated ART at 47 health facilities in central Kenya. Year cohorts were analyzed from the Comprehensive Patient Application Database (CPAD) and International Quality Care (IQCare) electronic medical databases, including temporal trends in outcomes and associated factors using multivariable competing risk regression analysis. There were more girls (2,453 [52.7%]) than boys, with most enrolled at World Health Organization (WHO) stage II (1,813 [37.7%]) or III disease (1,694 [35.1%]). Most of the children and adolescents (4,431 [96.4%]) did not have tuberculosis (TB) symptoms. Cumulative lost to follow-up (LTFU) incidence at 6, 12, 24, and 36 months were 5.0%, 9.9%, 22.9%, and 33.1%, respectively. Cumulative mortality incidence at 6, 12, 24, and 36 months were 0.7%, 1.0%, 1.2%, and 1.5%, respectively. The incidence of LTFU was higher among female children and adolescents, those initiated on tenofovir-based regimens, and those with presumptive TB symptoms. Mortality risk was higher among those with WHO stage III or IV disease, and children and adolescents on TB treatment or who had presumptive TB. Enrollment occurred at a young age and pediatric-friendly ART regimens were initiated at earlier WHO stages implying effective early infant diagnosis and treatment for all strategies, resulting in improved treatment outcomes. The higher retention rates in recent years as well as the lower retention after many years of follow-up underscore the importance of implementing longitudinal follow-up strategies targeting this population.
在肯尼亚,扩大艾滋病毒治疗服务的可及性改善了艾滋病毒儿童和青少年的治疗效果。但关于这些结果的数据很少。我们描述了 2004 年至 2014 年期间在肯尼亚中部由卫生解决方案中心支持的 47 个卫生机构中接受抗逆转录病毒疗法 (ART) 治疗的儿童和青少年的治疗效果的时间趋势。我们对在肯尼亚中部 47 个卫生设施中开始接受抗逆转录病毒治疗的 0-9 岁儿童(n=3519)和 10-19 岁青少年(n=1663)的儿童和青少年的回溯性数据进行了分析。从综合患者申请数据库(CPAD)和国际质量护理(IQCare)电子病历数据库中分析了年度队列,包括使用多变量竞争风险回归分析来评估结果的时间趋势和相关因素。女孩(2453 人,占 52.7%)多于男孩,大多数人处于世卫组织(WHO)疾病分期 II(1813 人,占 37.7%)或 III 期(1694 人,占 35.1%)。大多数儿童和青少年(4431 人,占 96.4%)没有肺结核(TB)症状。6、12、24 和 36 个月时的累积失访(LTFU)发生率分别为 5.0%、9.9%、22.9%和 33.1%。6、12、24 和 36 个月时的累积死亡率分别为 0.7%、1.0%、1.2%和 1.5%。女性儿童和青少年、接受基于替诺福韦的方案治疗的儿童和青少年以及有疑似结核病症状的儿童和青少年的 LTFU 发生率较高。患有 III 期或 IV 期疾病的儿童和青少年以及正在接受结核病治疗或有疑似结核病的儿童和青少年的死亡风险较高。登记时年龄较小,儿童友好型抗逆转录病毒方案在较早的 WHO 阶段开始实施,这意味着所有策略都进行了有效的早期婴儿诊断和治疗,从而改善了治疗效果。近年来较高的保留率以及多年随访后较低的保留率突显了针对这一人群实施纵向随访策略的重要性。